Genmab A/S - American Depositary Shares (GMAB)

Competitors to Genmab A/S - American Depositary Shares (GMAB)

Amgen Inc. 

Amgen competes with Genmab through its extensive experience in biopharmaceuticals and a diverse range of therapeutics, including in oncology. Amgen's capabilities in biologics give it an advantage in rapidly advancing drug development and acquiring existing products, while Genmab specializes in innovative antibody technologies. Genmab must differentiate itself through deeper specialization in advanced monoclonal antibodies, whereas Amgen benefits from a more extensive product portfolio and established market access.

Bristol Myers Squibb Company 

Bristol Myers Squibb (BMS) is well-known for its robust immuno-oncology portfolio. Their development of checkpoint inhibitors and other cancer therapies places them in direct competition with Genmab's monoclonal antibody drugs. BMS enjoys a leading position as a result of its established drug sales and comprehensive clinical trial networks, which enables it to rapidly enhance its drug offerings, whereas Genmab focuses on niche therapies and collaborations to enhance its market presence.

Gilead Sciences, Inc. 

While primarily known for its antiviral drugs, Gilead has made significant inroads into oncology, developing therapies that directly compete with Genmab’s offerings. Gilead’s competitive advantage arises from its strong financial foundation and innovation-driven approach to drug development. Genmab focuses on specific antibody platforms and targeted oncology therapies, while Gilead pursues broader indications through its diverse acquisition strategy, establishing a challenging landscape for Genmab in immuno-oncology.

Novartis AG

Novartis is a formidable competitor in the biopharmaceuticals sector, particularly in oncology, where it has developed several groundbreaking therapies. Competing directly with Genmab, Novartis leverages its extensive R&D capabilities, salesforce, and established clinical distribution channels to dominate the market. Genmab, however, aims to innovate through unique proprietary technologies and partnerships with larger pharmaceutical companies, striving to carve out a niche in areas where Novartis may be less focused. Novartis’ established market presence gives it an edge in competition.

Roche Holding AG

Roche is a significant player in the oncology space, rivaling Genmab with its strong portfolio of monoclonal antibodies and targeted therapies. Roche's established presence in the market and its extensive resources provide it with a competitive edge in research, development, and distribution capabilities. Genmab competes by leveraging its innovative platform technology in antibody research and development, but Roche’s broader pipeline and financial clout allow it to advance many more oncology therapies simultaneously.